ArticleThe Journal of dermatology2022

Safety, efficacy, and drug survival of the infliximab biosimilar CT-P13 in post-marketing surveillance of Japanese patients with psoriasis.

Akimichi Morita et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.